Barr has also announced that it is the first company to file an abbreviated new drug application with the FDA containing a paragraph IV certification for a generic version of Razadyne ER capsules, and therefore is entitled to 180-days of marketing exclusivity, as provided for under the Hatch Waxman Act. The company intends to launch its product shortly.